Chimeric antigen receptor (CAR) T cell therapy for solid tumors faces substantial biological and clinical barriers. In a phase 1 clinical trial, we show that a hypoxia-responsive, carcinoembryonic antigen-targeted CAR T cell therapy is safe and elicits meaningful antitumor responses in patients with refractory solid tumors. Efficacy was enhanced when CAR T cells were delivered intraperitoneally, suggesting this approach overcomes regional immunosuppressive barriers.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Albelda, S. M. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat. Rev. Clin. Oncol. 21, 47–66 (2024). A review article that delineates the challenges and potential therapeutic strategies for CAR T cell therapy for solid tumors.
Chen, Z., Han, F., Du, Y., Shi, H. & Zhou, W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct. Target. Ther. 8, 70 (2023). A review that describes how tumor hypoxia contributes to treatment resistance while simultaneously offering a strategic avenue for developing therapeutic approaches.
Kepenekian, V. et al. Advances in the management of peritoneal malignancies. Nat. Rev. Clin. Oncol. 19, 698–718 (2022). A review that details the clinical characteristics and therapeutic approaches for peritoneal metastases.
Zhu, X. et al. Hypoxia-responsive CAR-T cells exhibit reduced exhaustion and enhanced efficacy in solid tumors. Cancer Res. 84, 84–100 (2024). This work presents the findings from our earlier preclinical studies on hypoxia-responsive CAR T cell therapy.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Gao, Y. et al. Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trial. Nat. Cancer https://doi.org/10.1038/s43018-026-01124-3 (2026).
Rights and permissions
About this article
Cite this article
Regional delivery of hypoxia-responsive CAR T cells improves efficacy for solid tumors. Nat Cancer (2026). https://doi.org/10.1038/s43018-026-01129-y
Published:
Version of record:
DOI: https://doi.org/10.1038/s43018-026-01129-y
